Dr. Gandhi on Pembrolizumab/Chemo Findings in NSCLC and FDA Approval

Video

Leena Gandhi, MD, PhD, associate professor, Department of Medicine, director, Thoracic Medical Oncology Program, discusses the findings of cohort G of the KEYNOTE-021 trial that explored the combination of pembrolizumab (Keytruda) with carboplatin and pemetrexed for patients with advanced nonsquamous non-small cell lung cancer (NSCLC).

Leena Gandhi, MD, PhD, associate professor, Department of Medicine, director, Thoracic Medical Oncology Program, discusses the findings of cohort G of the KEYNOTE-021 trial that explored the combination of pembrolizumab (Keytruda) with carboplatin and pemetrexed for patients with advanced nonsquamous non-small cell lung cancer (NSCLC).

KEYNOTE-021 was initially a phase I study with a phase II expansion phase, Gandhi explains. In the phase II portion, 123 patients were randomized 1:1 to receive pembrolizumab plus first-line chemotherapy and half of whom had carboplatin/pemetrexed alone. The study, which was presented in 2016, showed that there was a progression-free survival benefit in those who received the immunotherapy/combination approval. However, there was not a benefit seen for overall survival with this novel regimen.

Based on these data, the FDA approved the regimen of pembrolizumab and carboplatin/pemetrexed in the first-line setting for these patients. The field is eagerly awaiting the data from the phase III study, adds Gandhi.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD